2019


- Parulekar WR, Berrang T, Kong I, Rakovitch E, Theberge V, Gelmon KA, Chia SKL,


---


• Gray R, Early Breast Cancer Trialists Collaborative Group, Early. Effects of prolonging adjuvant aromatase inhibitor therapy beyond five years on recurrence and cause-


2017


• Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Reagan PM, Miklos DB, Jacobson CA, Braunischweig I, Oluwole OO, Siddiqi T, Lin Y, Crump M, Kuruvilla J, Van Den Neste EW, Farooq U, Navale L, Go WY, Wiezorek JS, Gisselbrecht C. A Comparison of One Year Outcomes in ZUMA-1 (axicabtagene ciloleucel) and SCHOLAR-1 in Patients with


2016


• Cairns J, Ingle J, Dudenkov T, Kalari K, Buzdar A, Kubo M, Robson M, Ellis M, Goss P,

- Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon KA, Whelan TJ,


Donadey F, Franceschi E, Chinot OL, Winch C, Ding K, Mason WP. A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). J Clin Oncol 34[suppl; abstr LBA2]. 2016.


- Tinker A, Hirte H, Provencher D, Butler M, Ritter H, Tu D, Paralejas P, Grenier S, Hahn


2015


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[suppl; abstr e17710].


- Penniment MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(suppl 3; abstr 6)].


TJ, Montenegro A, O'Sullivan B, Parulekar WR. Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. J Clin Oncol 33[suppl; abstr 6000].


2014


- Bonomi M, Xu H, Laurie SA, Eisenhauer EA, Tu D, Pater JL, Seymour L, Bradbury PA. The association of treatment-emergent proteinuria (TEP) with baseline/treatment variables in patients (pts) treated with antiangiogenic tyrosine kinase inhibitors (AA-


chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. J Clin Oncol 32:5s[ suppl; abstr 4009]. 2014.


---

**2013**


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[Suppl; abstr 6557], 2013.

- Pavlakis N, Goldstein D, Sjoquist KM, Martin A, Tsobanis E, Yip S, Shannon J, Burge


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and associations with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[suppl, abstr 524], 2012.


• Siu LL, Shapiro JD, Jonker DJ, Karapetis CS, Zalcberg JR, Simes J, Couture F, Moore MJ, Price TJ, Siddiqui J, Nott LM, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski NM, Haydon A, Walters I, Tu D, O'Callaghan CJ, on behalf of NCIC CTG and AGITG. Final Analysis of the Phase III randomized trial of cetuximab (CET) + either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. J Clin Oncol 30[suppl, abstr 3504], 2012


• Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


Chapman JW, O’Callaghan C, Hu N, Ding K, Yothers GA, Catalano PJ, Shi Q, Gray RG,


• Hilton JF, Seymour L, Le Maître A, Tu D, Shepherd FA, Bradbury PA. An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine


- Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


2011.


- Stiff PJ, Unger M, Cook J, Constine LS, Coban S, Shea TC, Winter JN, Miller TP,


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


III randomised Gynaecologic Cancer InterGroup trial of concurrent bevacizumab and chemotherapy followed by maintenance bevacizumab, versus chemotherapy alone in women with newly diagnosed epithelial ovarian, primary peritoneal or fallopian tube cancer. Ann Oncol 21[Suppl 8, abstr LBA4], viii2, 2010.


- Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W, Belch A, Reiman T, Roy J, Shustik


- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


- Goss PE, Ingle JN, Martino S, Robert N, Muss H, Shepherd L, Pritchard KI, Livingston RB, Davidson N, Perez EA, Cameron D, Whelan T, Palmer M, Tu D. Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC


• Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It's a snap! Clinical Trials 6, 536, 2009.


• Pujade-Lauraine E, Mahner S, Kaern J, Gebski V, Heywood M, Vasey P, Reinhallar A, Vergote I, Pignata S, Ferrero A. A randomized, phase III study of carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in relapsed platinum-


- Mittmann N, Au HJ, Tu D, O’Callaghan CJ, Karapetis CS, Moore MJ, Zalcberg J, Simes


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

2008.

Part I], 437s, 2008.


---

2007


- Bramwell VHC, Pritchard KI, Tu D, Tonkin K, Vachhrajani H, Robert J, Arnold A, Vandenberg TA, O'Reilly SE, Graham B, Shepherd LE. How compliant are patients with


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


- White D, Kovacs M, Belch A, Stewart K, Chen C, Rubin S, Macdonald D, Harnett E,

2006


O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andrulis I, Pritchard KL. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.


Pollak M, Chapman JW, Shepherd L, Meng D, Richardson P, Wilson C, Orme B, Pritchard KL. Insulin resistance, estimated by serum C-peptide level, is associated with...
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2005

- Albain KS, Swann RS, Rusch VR, Turrisi AT, Shepherd FA, Smith CJ, Gandara DR,


• Eisenhauer EA. Combinations of agents for clinical development: which ones? How and when to develop these? Annals of Oncology 16[Suppl 3], 26, 2005.

• Gauthier I, Seymour L. Target effect and predictors of efficacy using laboratory correlative studies in early clinical trials: The Investigational New Drug Program at the NCIC Clinical Trials Group perspective. CIHR/NCIC National Meeting for Trainees, 2005.


- Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

- Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


- Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.

- Miller KD, Wang M, Gralow J, Dickler M, Cobleigh MA, Perez EA, Shenkier TN,


Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

Wong R, Paul N, Ding K, Brundage M, Fyles A, Pater J. Optimizing prophylaxis of

2004

- Delaunoit TP, Krock J, Sargent DJ, Green E, Alberts SR, Fuchs C, Ramanathan R,

- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.

- Kristensen GB, Vergote I, Eisenhauer E, Baekelandt M, Stuart G, Aavall-Lundquist E,


2003


Mazumdar M, Tu D. Efficiency of STRTA matched case-control studies with multiple controls per case in survival data setting. Controlled Clin Trials 24(3S), 112S, 2003.


2002


- Hirte H, Siu L, Gelmon K, Britten C, Eisenhauer E, Fisher B, Ptaszynski M, Onetto N.


- Tu D, Liu Y. A comparison of some statistical procedures for therapeut


2001


of tumor biopsy specimens from patients undergoing treatment with ZD1839. Clinical Cancer Research 7(suppl), 3708s, 2001.


inhibitor, NX 211, given on days 1, 2, 3 or days 1, 8 every 3 weeks to patients with advanced solid tumors. Proc.Am.Soc.Clin.Oncol. 19, 198a, 2000.


• Hirte H, Stewart D, Goel R, Chouinard E, Huan S, Elias I, Matthews S, Seymour L. NCIC CTG IND 113: Two phase I dose escalation pharmacokinetic studies of BAY 12-9566 in


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1998

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Bertelsen K, Kaern J, Simonsen E, Piccart M, Hoctin Boes G, Timmers P, Roy JA,
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Roche K, Paul N, Walker H, Zee B, Smuck B, Hiatt M, Brittain M. Measuring workload of


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


• Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


• Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


1994

- Mertens W, Eisenhauer E, Jolivet J, Ernst S, Moore M, Muldal A. Docetaxel in advanced


1993


• Myles J. Design issues of a pilot study to determine equivalent toxicity with G-CSF support. Clinical Trials in Oncology, 1993.


• Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)


1992


Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1991


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

1990

- Rusthoven J, Levin L, Eisenhauer E, Carmichael J. A phase I study of GM-CSF,


1989


- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.


1988


1987


1986

- Jolivet J, Landry L, Pinard MF, Eisenhauer E. Daily bolus x 9 trimetrexate: a phase I
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985


1984


1983

